Benzinga · Aug 26, 2026
FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.
NASDAQ · BBNX
Beta Bionics, Inc.
Healthcare · Medical - Equipment & Services
$16.59
Down-$0.83 (-4.76%)
Updated Sep 11, 2026, 3:38 AM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.29B
- P/E ratio
- -16.44
- Dividend yield
- 0.00%
- 52-week range
- $8.80 – $32.71
- Volume
- 957.71K
- Avg. volume
- 804.67K
Price performance
BBNX price history
1M range · 20 trading sessions · Daily adjusted prices
BBNX closed at $16.59 after 20 trading sessions, down 8.24% for the selected period.
- Last close
- $16.59
- Period change
- -8.24%
- Period low
- $16.59
- Period high
- $20.01
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $17.60 | $17.9517 | $16.4962 | $16.59 | 957.71K |
| Sep 9, 2026 | $19.14 | $19.54 | $17.258 | $17.42 | 848.75K |
| Sep 8, 2026 | $19.18 | $19.52 | $18.75 | $19.33 | 900.83K |
| Sep 4, 2026 | $19.55 | $19.97 | $19.00 | $19.42 | 1.41M |
| Sep 3, 2026 | $19.90 | $20.19 | $19.03 | $19.92 | 1.4M |
| Sep 2, 2026 | $18.99 | $19.57 | $18.905 | $19.415 | 645.12K |
| Sep 1, 2026 | $19.75 | $20.23 | $18.93 | $19.07 | 564.37K |
| Aug 31, 2026 | $19.42 | $20.00 | $19.02 | $19.95 | 434.87K |
| Aug 28, 2026 | $19.47 | $20.07 | $19.25 | $19.72 | 992.75K |
| Aug 27, 2026 | $19.22 | $19.64 | $19.12 | $19.54 | 518.92K |
| Aug 26, 2026 | $19.16 | $19.44 | $19.01 | $19.34 | 529.9K |
| Aug 25, 2026 | $19.92 | $20.00 | $18.615 | $19.34 | 710.96K |
| Aug 24, 2026 | $18.97 | $19.85 | $18.4701 | $19.73 | 864.53K |
| Aug 21, 2026 | $19.50 | $19.54 | $18.54 | $19.05 | 496.6K |
| Aug 20, 2026 | $20.00 | $20.735 | $18.48 | $19.48 | 1.93M |
| Aug 19, 2026 | $19.30 | $20.38 | $19.30 | $20.01 | 1.95M |
| Aug 18, 2026 | $17.56 | $19.08 | $17.50 | $19.02 | 1.98M |
| Aug 17, 2026 | $17.31 | $17.67 | $16.99 | $17.56 | 1.27M |
| Aug 14, 2026 | $18.12 | $18.15 | $17.49 | $17.57 | 935.92K |
| Aug 13, 2026 | $17.33 | $18.325 | $17.04 | $18.08 | 1.5M |
Latest BBNX news
The latest Smart Investors Daily articles mentioning BBNX.
Stock researchCompany · Overview
BBNX research
Overview
Company profile and research snapshot.
Company profile
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $31.00
- Implied upside
- —
- Analysts
- 16
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 21, 2026 | William Blair | Market Perform | — |
| Jul 15, 2026 | Goldman Sachs | Buy | — |
| Jul 13, 2026 | Truist Securities | Buy | — |
| May 27, 2026 | Goldman Sachs | Buy | — |
| May 18, 2026 | B of A Securities | Neutral | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 21, 2026
William Blair Initiates Coverage On Beta Bionics with Market Perform Rating
William Blair analyst Steven Lichtman initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Market Perform rating.
Benzinga · Aug 21, 2026
Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics
William Blair initiates coverage on Tandem Diabetes Care and Beta Bionics, highlighting their growth potential in the insulin pump market.
SeekingAlpha · Jul 31, 2026
Beta Bionics, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-07-31. The following slide deck was published by Beta Bionics, Inc.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
